Ovotoxicant VCD disrupts oocyte meiosis in mice by impairing m6A/IGF2BP3-mediated mRNA stability Authors: Yang Li, Yuling Zhou, Jian Liu, Guangning Nie, Fangping Cheng, Hongyan Yang Published: 2025 ABSTRACT AbstractEnvironmental toxicants pose a significant threat to female reproductive health, yet the molecular mechanisms through which they impair oocyte quality are often unclear. Although the industrial chemical 4-vinylcyclohexene diepoxide (VCD) is known to cause ovarian follicle loss, how it disrupts essential processes such as meiosis remains poorly understood. Here, we show that VCD exposure triggers meiotic failure in mouse oocytes by altering a key RNA modification pathway known as m6A methylation. VCD treatment reduces ovarian reserve, elevates oxidative stress, and causes severe chromosome segregation defects. We find that VCD dysregulates the expression of m6A writers and erasers, leading to altered methylation of transcripts critical for cell division and meiosis. Specifically, VCD downregulates the RNA-binding protein IGF2BP3, which destabilizes target genes required for chromosome alignment and spindle assembly. Our results reveal how an environmental toxin can cause epitranscriptomic dysregulation and meiotic failure, providing a new perspective on pollutant-induced fertility decline. This work highlights the m6A pathway as a potential therapeutic target and underscores the broader reproductive risks posed by chemical exposures. Subject terms: Molecular medicine, Risk factors, Experimental models of disease, Infertility, Methylation Introduction 4-vinylcyclohexene diepoxide (VCD) is the diepoxide metabolite of 4vinylcyclohexene (VCH)1. Industrially, VCD is widely used as a chemical intermediate and reactive diluent for diepoxides and epoxy resins, and it is present in the production of rubber tires, flame retardants, antioxidants, flavors, pesticides, plasticizers2,3. Thus, humans can be exposed to VCD in both directly and indirectly, risking excessive exposure4. VCD is regarded as a hazardous industrial chemical and environmental pollutant because of its widely reported reproductive toxicity. Therefore, it is important to study VCD exposure in the population and investigate its impact on female reproductive ability. VCD targets and destroys primordial and primary follicles in rodents and primates, leading to premature ovarian insufficiency (POI) by accelerating follicular depletion4,5. While pathways such as Kit ligand suppression, Bcl-2-mediated apoptosis, and mTORC2 dyfunction are associated with VCD’s ovotoxicity2,6,7, the exact mechanisms affecting oocyte transcriptomic balance remain unclear. During oocyte meiosis, maternal RNA is stored for maturation and embryonic development, with transcription pausing at the final growth stage and resuming post-fertilization8. This is vital, as oocytes in primordial follicles,which are arrested in meiotic prophase I for years, depend on post-transcriptional regulation of maternal mRNAs due to transcriptional silencing in late oogenesis9. Emerging evidence highlights N6-methyladenosine (m6A) RNA methylation as a master regulator of maternal mRNA stability, meiotic resumption, and cytoskeletal remodeling in oocytes10–12. As the most prevalent internal mRNA modification, m6A plays pivotal roles in post-transcriptional regulation by modulating mRNA processing, translation, and decay10. Its role in the reproductive system, particularly in oocyte development and maturation, has been increasingly recognized, influencing oocyte quality and ovarian function by regulating key gene expression13,14. Importantly, m6A has been shown to mediate cellular responses to environmental stressors and disease pathogenesis15,16. For instance, microplastics and heavy metals significantly alter m6A levels, impacting genes related to RNA methylation, including methyltransferases, demethylases, and “readers“17. Additionally, prepubertal testicular injury from DEHP is linked to increased m6A levels and changes in FTO and YTHDC2 expression18. These findings collectively suggest that environmental pollutants may perturb gene expression and cellular function via m6A-mediated mechanisms, ultimately contributing to disease etiology19. Although VCD’s detrimental effects on ovarian function are well-documented, its specific impact on m6A modification during follicular atresia remains unexplored. Building upon our prior work1,20–24, we hypothesize that VCD may impair oocyte meiosis by interfering with regulatory mechanisms governing follicle activation or oocyte maturation, potentially leading to developmental arrest, apoptosis, and subsequent follicular depletion. This study aims to elucidate VCD-induced alterations in oocyte m6A modifications and their functional consequences. Through MeRIP-seq analysis, we will systematically characterize m6A epitranscriptomic changes and evaluate their implications for oocyte development. Our findings are expected to advance the mechanistic understanding of VCD-induced ovarian decline and identify novel therapeutic targets for preventing and treating POI/primary ovarian failure (POF), ultimately contributing to improved strategies for preserving female reproductive health. Results VCD exposure affected ovarian function and follicle development in mice Experimental Design and Timeline: As shown in Supplementary Fig. 1A, the weight and dimensions of each mice’ s ovaries were measured, with the long (L, mm) and short (S, mm) diameters recorded. Ovarian volume was calculated using V = L * S2/ 2(mm3). Figure 1A, B illustrate that varying VCD concentrations (80, 160, or 240 mg/kg) significantly reduced ovarian volume and weight in a dose-dependent manner (p < 0.05, p < 0.01). Anti-Müllerian hormone (AMH), an indicator of ovarian reserve in mice, showed a dose-dependent decrease in serum levels with VCD exposure, asdetermined by ELISA (p < 0.05, p < 0.01, p < 0.001; see Supplemental Fig. 1B). VCD exposure affected ovarian function and follicle development in mice. A, B Comparison of ovary weight and volume in each group (Ovarian volume(mm3),Ovarian weight (mg), n = 12). C Morphological changes of ovarian tissue in mice (HE, ×40, scale bar = 625 μm, scale bar = 100 μm). D Number of primordial follicles, primary follicles, secondary follicles, antral follicles and Mature follicles in four groups. Data are shown as the mean ± SD, n = 6, VS. control, *P < 0.05, **P < 0.01, ***P < 0.001. CL: corpus luteum; red arrow,antral follicles; Black arrow, Atretic follicle. The maximum ovarian cross-sections across four groups of mice showed that control ovaries had numerous antral follicles at various developmental stages, while VCD-treated ovaries displayed abnormal histology (Fig. 1C and Supplemental Fig. 1C). Follicle counts, done to avoid omissions and double counting, were significantly lower in the VCD group compared to controls. VCD caused significant loss of oocytes in all follicle stages, including primordial, primary, secondary, antral, and mature follicles, compared to controls (p < 0.001, p < 0.001, and p < 0.01, respectively; Fig. 1D). Exposure to VCD significantly impairs the number of oocytes acquired and the ability to mature in vitro The experimental design and hormone treatments are shown in Fig. 2A. After superovulation, oocytes were collected for evaluation. VCD exposure significantly reduced the number of oocytes at the GV and MII stages in mice (Fig. 2B, C and Supplemental Fig. 1D). Oocyte nuclear maturation was assessed by GVBD and PB1 extrusion rates. While GVBD rates were unchanged, PB1 extrusion rates significantly decreased with VCD treatment (p < 0.05, p < 0.05, and p < 0.001; Fig. 2D–F). VCD also negatively impacted oocyte morphology, increasing the fragmentation rate significantly (p < 0.001; Fig. 2G, H). In addition, we explored the effects of different concentrations of VCD on the in vitro maturation of young oocytes. After treating in vitro-mature oocytes with 0.5, 1, and 2 mM VCD for 1 h, the GVBD rate decreased by 26.3, 31.2, and 43.5% (P < 0.001), and the polar body excretion rate decreased by 38.8, 60.4, and 73.6% (P < 0.001), and the mortality rate of oocytes showed a dose-dependent increase (P < 0.001; Supplemental Fig. 2). Exposure to VCD significantly impairs oocyte developmental ability. A Experimental Design and hormone treatment. B Representatives of GV-stage oocytes from each group after PMSG 48 h injection. C The ampullae of oviduct and MII oocytes obtained in each group after HCG 14 h injection, and the magnified oocytes showed the typical morphology of oocytes. D The number of GV-stage oocytes obtained in each group (n = 249, 136, 107, 58). E–F The GVBD and polar body extrusion statistics of GV-stage oocytes with control, 80, 160, and 240 mg/kg VCD groups after IVM culture, respectively (GVBD statistics of oocytes in each group: n = 242, 54, 48, 38; the number of oocytes in each group was calculated by PB1 rate: n = 201,46, 41, 32). (G, H) The number of oocytes collected at the MII stage in each group (n = 224, 121, 61, and 35), along with the fragmentation rate. Data are shown as the mean ± SD. VS control, *P < 0.05, **P < 0.01, ***P < 0.001. Exposure to VCD significantly impairs the functional fertilization ability To further investigate the impact of VCD on oocyte quality, MII stage oocytes were obtained, subjected to in vitro fertilization, and assessed for fertilization capacity and embryonic developmental potential across different groups. The findings revealed a significant reduction in both the in vitro fertilization rate and blastocyst formation rate in the VCD treatment group (P < 0.001; see Fig. 3A–C). The effect demonstrated a clear dose-dependent relationship. Effects of VCD on in vitro fertilization efficiency. A Representative images of two-cell embryos developed from in vivo fertilized oocytes from CON and VCD group mice. Scale bar, 100 or 20 μm. B The fertilization rate was quantified in the CON (n = 85), 80 mg/kg VCD (n = 39),160 mg/kg VCD (n = 32) and 240 mg/kg VCD (n = 28). ***P < 0.001. C The proportion of blastocyst formation was quantified in the CON (n = 85), 80 mg/kg VCD (n = 39),160 mg/kg VCD (n = 32) and 240 mg/kg VCD (n = 28). ***P < 0.001. Data are shown as the mean ± SD of at least three independent experiments. Statistical significance was determined by a two-tailed unpaired t-test. VCD-induced oocyte quality deficits are associated with mitochondrial dysfunction and DNA damage Cytoplasmic maturation is vital for oocyte quality, influencing fertilization and embryonic development. We assessed mitochondrial dynamics as an indicator of cytoplasmic maturity. MitoTracker green staining revealed that mitochondria in normal oocytes were evenly distributed around the spindle (Fig. 4A and Supplemental Fig. 2). VCD exposure disrupted this distribution, reducing cytoplasmic signals and causing chromosome aggregation. Mitochondrial dysfunction was evident, with VCD-exposed oocytes showing increased fluorescence due to higher ROS levels and altered membrane potential compared to controls (P < 0.01, P < 0.001; Fig. 4B–E). VCD likely affects mitochondrial membrane potential and distribution by increasing ROS, leading to DNA damage and compromised oocyte structure and quality (P < 0.001; Fig. 4F and G). Effects of VCD on the quality of oocytes. A MitoTracker Green staining was used to detect mitochondrial distribution in oocytes; scale bar, 10 μm. Mitochondria was used to stain nuclei (Green). B Representative images of ROS generation in control and VCD-treated oocytes; scale bar, 30 μm. C Statistical analysis of fluorescence intensity of ROS in mouse oocytes of each group (***P < 0.001). D JC-1 staining assess mitochondrial membrane potential in the oocytes Red fluorescence represents healthy mitochondria, while green fluorescence indicates impaired mitochondria. Quantitative analysis of the red/green fluorescence ratio was performed to evaluate changes in mitochondrial membrane potential; scale bar, 30 μm. E Statistical analysis of fluorescence intensity of JC-1 in mouse oocytes from each group (**P < 0.01, ***P < 0.001). F immunofluorescence test of γ-H2AX evaluating DNA damage in oocytes. Scale bar, 20 μm. G Statistical analysis of fluorescence intensity of γ-H2AX in mouse oocytes of each group (***P < 0.001). H Effects of VCD on spindle/chromosome configuration in mouse oocytes. Representative images of normal and abnormal spindle and chromosome morphology in oocytes. Scale bar, 20 μm. I, J The percentages of misaligned chromosomes and aberrant spindles rates were quantified in oocytes at metaphase II from CON (n = 25), 80 mg/kg VCD (n = 19),160 mg/kg VCD (n = 17) and 24 0 mg/kg VCD (n = 18). Data are shown as the mean ± SD of at least three independent experiments. Statistical significance was determined by two-tailed unpaired t-test (**P < 0.01, ***P < 0.001). In vitro treatment with VCD (0.5, 1, 2 mM) had significant dose-dependent effects: GVBD rate decreased by 26.3, 31.2, and 43.5%, and polar body extrusion rate decreased by 38.8%, 60.4%, and 73.6%, respectively (P < 0.001). Higher VCD concentrations caused mitochondria to become diffusely fragmented. VCD treatment increased DNA damage levels in a concentration-dependent manner (Supplemental Fig. 3). Meiosis requires the proper assembly of the spindle apparatus and accurate chromosome separation for gamete formation. Immunofluorescence staining showed that, in the control group, the spindle apparatus during metaphase I ensured correct chromosome alignment and microtubule attachment to centromeres. However, the VCD-treated group exhibited more disorganized spindles, chromosome misalignment, and incorrect centromere-microtubule attachments in oocytes (P < 0.01, P < 0.001; Fig. 4H–J). VCD exposure likely increases DNA damage in oocytes by generating reactive oxygen species (ROS) and disrupting mitochondrial function, leading to decreased oocyte quality and reduced fertilization capacity. VCD decreased RNA m6A levels and changed the expression of methyltransferases, demethylases and readers m6A mRNA modification is crucial for reproductive function, and environmental endocrine disruptors can alter cell function by affecting mRNA methylation. Dot hybridization showed that VCD exposure reduced ovarian m6A methylation levels compared to controls (P < 0.05, P < 0.01; Fig. 5A, B), suggesting a link between decreased m6A levels and VCD-induced ovarian dysfunction. m6A is a reversible modification involving specific enzymes and reader proteins. VCD’s impact on Mettl3, Mettl14, Fto, Alkbh5, Ythdf1, Ythdf2, Ythdf3, Igf2bp1, Igf2bp2, and Igf2bp3 was evaluated. Figure 5C shows VCD treatment decreased Mettl3, Alkbh5, and Igf2bp3 levels, while Fto and Ythdf2 levels increased. Protein analysis confirmed these changes, with ALKBH5 and IGF2BP3 proteins decreasing and FTO and YTHDF2 proteins increasing (Fig. 5D, E and Supplemental Fig. 4). Different concentrations of VCD treatment reduced both m6A modification levels and IGF2BP3 fluorescence expression (Supplemental Fig. 5). Global m6A RNA modification and expression of methylatio-related enzymes after 160 mg/kg VCD treatment in mice ovaries. A, B Dot blot method was used to assess the m6A levels in mice ovaries after VCD treatment. Each column represents an independent biological sample (n = 3, 1, 2 and 3 represent three biological samples). The upper row shows the m6A signal (Anti-m6A antibody, Synaptic Systems #202003), and the lower row shows the total RNA control (methylene blue staining). The signal intensity was quantified by ImageJ and normalized with total RNA as the internal reference. The bar chart showed the mean ± SEM (unpaired t-test, **P < 0.05, ***P < 0.01). C RT-qPCR was used to detect the gene expression of m6A related methylases in ovary of mice in each group (VCD represented 160 mg/kg VCD group, n = 3). D, E The expression of m6A demethylases (ALKBH5 and FTO), m6A reader YTHDF2, and IGF2BP3 protein expression levels after VCD treatment in mouse ovaries (n = 3). Data are shown as the mean ± SD. VS control, *P < 0.05, **P < 0.01, ***P < 0.001. Based on the comprehensive analysis of the expression test results of gene and protein expression test results, it is speculated that IGF2BP3 proteins may play an important role in the changes of ovarian function induced by VCD. Transcriptome-Wide m6A-Seq Revealed Global m6A Modification Patterns after VCD exposure The study employed transcriptome-wide m6A sequencing to investigate global m6A modification patterns in mouse ovarian tissues following VCD exposure, aiming to understand the mechanisms of ovarian injury. Two tissue groups underwent m6A-seq and RNA-seq, focusing on methylated RNA immunoprecipitation sequencing (Fig. 6A). m6A methylation was divided into four transcriptional segments: 1st exon, 5’UTR, 3’UTR, and other exons, with the 3’UTR being the primary modification site. No distribution differences were found between groups (Fig. 6B). Saturation curves indicated reduced m6A modifications in ovarian tissue after VCD exposure (Fig. 6C), consistent with Dot blot results. Transcriptome-Wide m6A-Seq reveals global m6A modification Patterns after VCD exposure. A Experimental workflow related to m6A RNA immunoprecipitation (MeRIP). B Distribution and percentage of m6A methylation peaks between CON and VCD groups. C m6A saturation curve, where the X-axis represents the number of sequencing reads and the Y-axis represents the number of detected m6A sites. The curve that reaches saturation first indicates higher m6A modification abundance. D The top motifs enriched across the m6A peaks identified from CON and VCD group. E Model analysis using ChIP-seq algorithm to identify m6A peaks, displaying the number of common m6A peaks for CON and VCD groups. F Volcanic plots of differentially modified m6A genes (VCD group vs. control group). Each point represents a gene, with the horizontal axis representing log2 Fold Change and the vertical axis representing -log10 (adjusted p-value). Blue and red dots represent significantly differentially expressed genes (|log2FC | > 1, adjusted p value < 0.05, bilateral Wald test, DESeq2 algorithm). The data are based on three biological replicates (n = 3). G The differential peaks between the CON and VCD groups. RNA methylation and demethylation involve various proteins interacting with methylation site motifs. Motif prediction and differential analysis were performed for each sample group(Fig. 6D and Supplementary Data 1). The main m6A motif in the CON group was GAACU, while in the VCD group, it was AAACU. The CON group had 8643 m6A peaks, and the VCD group had 8849, with 7741 peaks common to both (Fig. 6E and Supplementary Data 2). Figure 6F,G include a volcano plot and bar chart of differential peaks; these findings highlight a significant difference in m6A modification patterns between the CON and VCD groups. Compared to the CON group, the VCD group had 902 new peaks and lost 1108 peaks. Additionally, 257 peaks were significantly upregulated and 174 were downregulated in the VCD group(Supplementary Data 3). The top 20 differentially methylated peaks are in Supplemental Table 4. Differentially expressed genes (DEGs) during the occurrence and development of Ovarian injury induces By VCD In the RNA-seq dataset (m6A-seq input library), we identified significant differences in the overall mRNA expression patterns between the control (CON) samples and the VCD samples. The analysis of mRNA expression profiles revealed that, compared to the control group, 847 mRNAs exhibited significant alterations in the VCD group, with 163 mRNAs being upregulated and 684 mRNAs being downregulated (fold change > 2, p < 0.05; Fig. 7A, B and Supplementary Data 4). Furthermore, based on the integrated GametesOmics dataset, we found that a total of 539 differentially expressed genes were enriched in the oocyte database, directly indicating the relationship between VCD-induced down-regulation and oocyte-specific transcription programs(Supplemental Fig. 6 and Supplementary Data 5). The top 20 altered genes are presented in the supplementary materials Table S5. Figure 7C illustrates the results of the Gene Ontology (GO) enrichment analysis, demonstrating the enrichment of differentially expressed genes in the categories of Biological Process, Cellular Component, and Molecular Function. The most significant differences were observed in the regulation of DNA-templated transcription, cytoplasm, and protein binding. Furthermore, KEGG pathway analysis indicated that the aberrant CON/VCD genes were closely associated with the cell cycle, motor proteins, p53 signaling pathway, and oocyte meiosis (Fig. 7D and Supplementary Data 6). Differentially expressed genes (DEGs) involved in ovarian damage caused by VCD. A The expressed genes (DEGs) between the CON and VCD groups. Compared to the control group, 163 mRNAs were upregulated and 684 mRNAs were downregulated (|log2(FC)| ≥ 1, p < 0.05). B Annotation heatmap of DEGs showing significant changes. C Visualization results of GO (Gene Ontology) enrichment analysis. The enrichment of differentially expressed genes in Biological Process, Cellular Component, and Molecular Function is demonstrated. Different colors or regions in the figure may correspond to different log10(P.UE) intervals. The darker the color, the smaller the P value and the more significant the enrichment results. D Pathway analysis of DEGs in VCD samples compared with CON samples. Abnormal m6A-Modified Genes Were Enriched in oocyte meiosis Motor Proteins Signaling Pathways MeRIP-seq and RNA-seq identified differentially methylated (DMGs) and expressed genes (DEGs) between CON and VCD, respectively. Combined analysis categorized genes into four groups: 140 hypermethylated and upregulated (hyper-up), 140 hypermethylated and downregulated (hyper-down), 237 hypomethylated and upregulated (hypo-up), and 327 hypomethylated and downregulated (hypo-down) (Fig. 8A, Supplemental Fig. 7 and Supplementary Data 7). Based on criteria of diff.log2.fc ≥ 0.585 or ≤ −0.585, log2(fc) ≥ 2 or ≤ −1, and p-value ≤ 0.05, significant gene targets associated with VCD through m6A methylation were identified, including Alpk3, Cep55, Ttyh1, Mybl2, Bub1, Kbtbd8, Cnr1, Cenpa, Avil, Mapk15, Espl1, Gdf9, and Polq (Fig. 8A, B and Table 1). More “hypo-up” and “hypo-down” genes were found than “hyper-up” and “hyper-down” genes, with larger fold changes and smaller p-values, indicating m6A modification is closely linked to mRNA downregulation in VCD, suggesting a negative correlation. Conjoint analysis of m6A-RIP-seq and RNA-seq data. A Distribution of genes with a significant change in both m6A and mRNA levels in CON group compared with VCD group (log2 (fc)≥ 0.585 or ≤ −0.585, p ≤ 0.05, diff.log2.fc≥0.585 or ≤−0.585, diff.p ≤ 0.05). B Two groups of differentially expressed genes were identified using a Venn diagram. C KEGG enrichment analyses of mRNAs with differential methylation and expression. D Validation of m6A level changes in 15 genes in the CON and VCD groups by RIP-m6A qPCR assays. *p < 0.05, **p < 0.01, ***p < 0.001 by two-tailed Student’s t-test. Data represent the mean ± SEM (n = 3). Table 115 genes exhibit a significant change in both m6A and mRNA transcript abundance (CON vs. VCD)Gene namePatternChromosomem6A level changemRNA level changePeak regionPeak startPeak enddiff.log2.fcp-valuelog2.(fc)p-valueAlpk3Hyper-downchr1Exon1429185971429198551.010.00−1.640.00Cep55Hypo-downchr13’ UTR256760618256760766−1.480.04−1.060.01Ttyh1Hypo-downchr13’ UTR7373581873736057−0.790.01−1.070.00Mybl2Hypo-downchr3Exon159440687159441046−0.680.00−1.090.00Bub1Hyper-downchr33’ UTR1203744721203748020.730.02−1.450.00Kbtbd8Hyper-downchr43’ UTR1271703841271748710.700.00−1.080.00Cnr1Hyper-downchr5Exon49328697493290851.440.01−1.530.00CenpaHyper-downchr63’ UTR27073336270739652.170.00−1.380.00AvilHyper-downchr73’ UTR70310320703105580.660.03−1.060.01Mapk15Hypo-downchr73’ UTR117060690117060958−2.220.00−2.010.00Espl1Hyper-downchr7Exon1439155041439168690.610.00−1.130.00Gdf9Hypo-downchr103’ UTR3878925838792940−0.730.00−2.420.00PolqHyper-downchr11Exon66618802666204181.350.00−1.230.00Npm2Hypo-downchr15Exon5234428052344629−0.900.03−2.460.00Dcdc2Hyper-downchr17Exon41843613419596810.900.03−1.260.03 15 genes exhibit a significant change in both m6A and mRNA transcript abundance (CON vs. VCD) By analyzing differentially methylated and expressed genes, we identified genes significantly linked to the cell cycle, oocyte meiosis, and motor proteins (Fig. 8C and Supplementary Data 8). We validated our m6A-seq data using RIP-m6A qPCR assays, confirming consistency with sequencing results and the reliability of our data (Fig. 8D and Supplementary Figs. 4C). This indicates that ovarian tissue exposed to VCD shows a distinct m6A modification pattern compared to normal tissue, both across the transcriptome and at specific genes. Abnormal oocyte meiosis induced by VCD exposure is associated with decreased IGF2BP3 resulting in Bub1/ Cenpa/Polq mRNA abundance RNA-Seq analysis showed that maternal mRNAs related to the cell cycle, oocyte maturation, and meiosis decreased after VCD exposure in mice. MeRIP-Seq linked this mRNA down-regulation to m6A modification, showing a negative correlation. Analysis suggests that IGF2BP3, an mRNA-stabilizing protein via m6A recognition, is crucial. Reduced IGF2BP3 weakens mRNA stabilization, potentially increasing degradation25. To test this, we screened siRNAs targeting Igf2bp3 in oocytes and chose siRNA-1 for further study (Fig. 9A). Western blot and immunofluorescence confirmed IGF2BP3 knockdown (Fig. 9B, C). IGF2BP3 was found in both the nucleus and cytoplasm of MI oocytes, and its downregulation disrupted spindle formation and chromosome segregation. After siRNA-1 injection, the polar body extrusion rate in MII oocytes decreased, with some showing large polar bodies or symmetrical division. Igf2bp3 knockdown by siRNA-1 also significantly reduced oocyte fertilization ability and led to abnormal embryonic development (Fig. 9D). Functional validation of IGF2BP3 in oocyte maturation and early embryonic development. A Diagram of oocyte microinjection. B Western blot (WB) verified the expression of IGF2BP3 in MI-stage oocytes after injection of Igf2bp3 siRNA into GV-stage oocytes. C Confocal immunofluorescence staining for IGF2BP3 (purple) in oocytes. DAPI was used to stain nuclei (blue). Microtubules were labeled with an α-tubulin antibody (green). Scale bar, 20 μm. D Images of control siRNA (Control) and Igf2bp3 siRNA-microinjected oocytes after MII-phase polar body extrusion and in vitro fertilization, showing 4-cell embryo development. Scale bar, 100 μm. E qRT-PCR analysis of mRNA levels in oocytes (n = 3). F Confocal immunofluorescence staining for IGF2BP3, CENPA, and POLQ (purple) in oocytes. DAPI was used to stain nuclei (blue). Scale bar, 20 or 10 μm. *P < 0.05, **P < 0.01, ***P < 0.001. Data represent the mean ± SEM (n = 3). MeRIP-Seq analysis identified differentially methylated genes, and qRT-PCR confirmed significant downregulation of Igf2bp3 mRNA at the GV stage, possibly affecting Bub1, Cenpa, and Polq mRNA stability (Fig. 9E). Oocyte immunofluorescence showed decreased protein levels of these genes (Fig. 9F). These results indicate that IGF2BP3, as an m6A reader, is crucial for stabilizing maternal mRNAs important for meiosis and DNA repair. Discussion Industrialization and lifestyle changes have led to significant environmental pollution, posing health risks, especially to women’s reproductive health26. The industrial chemical 4-vinylcyclohexene diepoxide (VCD), used in plastics, pesticides, and rubber, damages ovarian follicles in rodents and primates, causing ovarian failure4,7. Our study confirms that VCD reduces AMH levels and disrupts folliculogenesis, similar to what is observed in human POI and rodent models. New evidence shows VCD also causes transgenerational fertility and developmental issues27. While VCD’s reproductive risks are clear, its molecular mechanisms, especially regarding oocyte vulnerability, remain unclear and require further study. m6A Dynamics as a Novel Regulatory Axis in Ovarian Toxicity: Recent studies underscore the significance of m6A RNA methylation as a critical factor in environmental reproductive toxicity15. Recognized as the most prevalent mRNA modification, m6A plays a crucial role in RNA processing and has been associated with gametogenesis issues28,29. Exposure to VCD has been shown to reduce m6A methylation in ovarian tissue and alter the expression of associated enzymes, such as METTL3, FTO, ALKBH5, and IGF2BP3, consistent with our previous findings in rat models1. These results indicate that the dynamic changes of m6A are both biomarkers and functional drivers of VCD-induced ovarian injury. In this study, MeRIP-seq/RNA-seq analysis revealed a notable inverse relationship between m6A methylation and transcript abundance in ovaries exposed to VCD. Hypomethylated mRNAs encoding cell cycle regulators such as Bub1, Cenpa, and Polq exhibited destabilization, thereby disrupting essential pathways responsible for oocyte meiosis and genomic stability, this point was also mentioned in previous studies30. The detection of methyltransferases identified IGF2BP3 as a pivotal element in this regulatory network. As an m6A-dependent RNA stabilizer31, the knockdown of IGF2BP3 mimicked the effects of VCD exposure, leading to a reduction in the mRNA half-lives of Bub1 (spindle assembly checkpoint), Cenpa (centromere integrity), and Polq (DNA repair). This convergence suggests that VCD-induced suppression of IGF2BP3 creates a “perfect storm” for meiotic catastrophe: impaired spindle assembly checkpoint signaling allows for chromosome missegregation, while compromised DNA repair mechanisms heighten the risk of aneuploidy. Notably, the prolonged meiotic arrest in primordial follicles, which can last for decades in humans, may exacerbate these defects, making oocytes particularly vulnerable to chronic m6A dysregulation. It should be pointed out that our whole-tissue sequencing analysis cannot distinguish cell type-specific effects. Previous studies have shown that VCD may target oocytes and granulosa cells differently.We agree that future studies using isolated oocytes and somatic cells are essential to resolve this question conclusively. Recent studies have demonstrated that IGF2BP3 is involved in orchestrating transcript localization, such as meiotic spindle-associated RNAs, and in initiating translation through interactions with 5’UTR m6A “cap” structures32. In oocytes, such spatial regulation is essential for asymmetric division and cytoplasmic maturation. Furthermore, as reported in Science8, the mitochondrial membrane-free region (MARDO) serves as a critical site for the storage of maternal mRNA in oocytes. IGF2BP3, as an RNA-binding protein, may play a significant role in the storage and degradation of maternal mRNA during oocyte meiosis. Although our study established a strong association between VCD exposure and down-regulation of IGF2BP3, the causal relationship and related mechanisms remain to be verified. Furthermore, although we suggest that mitochondrial dysfunction (such as changes in mitochondrial membrane potential and mitochondrial distribution) is a potential factor for the dysregulation of VCD-m6A/IGF2BP3, the direct link between mitochondria and the m6A mechanism requires further exploration. For instance, does m6A modification regulate mitochondrial dynamic balance by maintaining the function of the mitochondrial electron transport chain? Epigenetic regulation, such as m6A mediated by mitochondrial metabolites like ROS. Future work will adopt oocyte-specific Igf2bp3 knockout models or rescue experiments combined with single-cell RNA sequencing (scRNA-seq) and spatial multi-omics techniques (such as scMeRIP-seq) to clarify its central role in the mechanism33. The integrated analysis of ELISA, dot blot hybridization, and m6A-seq data revealed the VCD-induced bidirectional m6A remodeling pattern: While the overall m6A level decreased, the stress-responsive transcripts showed enhanced methylation. This bimodal pattern is consistent with findings related to chemotherapy-induced ovarian damage, wherein stress-responsive genes acquire protective m6A modifications to enhance translation. We hypothesize that VCD induces a selective redistribution of m6A, leading to the depletion of “housekeeping” transcripts, such as those involved in the cell cycle, while enriching mRNAs associated with stress adaptation. The upregulation of YTHDF2 observed in this context supports this hypothesis, as this degradation-promoting “reader” typically targets m6A-modified mRNAs34. Consequently, VCD may utilize YTHDF2 to eliminate essential meiotic transcripts while preserving pro-survival messages, representing a maladaptive survival mechanism in long-lived oocytes35. This dual regulatory feature highlights the complexity of m6A dynamics in the context of VCD toxicity- the coexistence of overall deletion and local gain, which needs to be further clarified in the future. Methods Animal The study used SPF-grade female ICR mice(28 days old, 44825300004200) from the Guangdong Medical Laboratory Animal Center (License No. SCXK [Guangdong] 2020-0053). The protocol was approved by the Animal Ethics Committee of the Guangdong Experimental Animal Center of Traditional Chinese Medicine (Ethics No. 20218075). Mice were kept in a standard SPF environment at 22 °C ± 2 °C, 50–60% humidity, and a 12 h light/dark cycle, with free access to food and water. Experiments were conducted at the Laboratory Animal Center of Guangdong Hospital of Traditional Chinese Medicine (License: SYXK [Guangdong] 2023-0342). VCD treatment Mice were randomly assigned to the control, 80 mg/kg, 160 mg/kg, or 240 mg/kg VCD group (n = 12). The VCD groups received intraperitoneal injections of VCD (94956, Sigma-Aldrich) at their respective doses, diluted in sesame oil (M07A9E67472, Yuan Ye Biotech, Shanghai), for a period of 15 consecutive days. After a 90-day period, the mice were euthanized using an overdose of pentobarbital sodium or super-stimulated to obtain oocytes. Serum samples were collected for the detection of Anti-Müllerian hormone(AMH) hormones, AMH levels were detected referring to the instructions of the ELISA kits (CSB-E11162r, CUSABIO BIOTECH, Wuhan). Ovaries were harvested and weighed for subsequent pathological examination and expression analysis. Superovulation and oocyte collection For collection of GV oocytes, Ninety days subsequent to the final VCD injection, mice were injected with 10 I.U. pregnant mare serum gonadotropin (PMSG) and then sacrificed 48 h later. To release cumulus-oocyte complex (COCs), hormone-stimulated ovaries were dissected in M2 medium (Sigma, M7167). COCs were repeatedly mechanically aspirated to facilitate degranulation. Only full-grown GV oocytes with good morphology were selected and then cultured in M16 medium under mineral oil (M8410, Sigma) at 37 °C with 5% CO2. In order to harvest in vivo MII oocytes, superovulation was performed on female mice by injection of 10 I.U. PMSG followed with 10 I.U. human chorionic gonadotropin (hCG) injection 48 h later. Fourteen hours after hCG treatment, COCs were obtained through puncturing oviduct ampullae with needles. Somatic cells were removed by brief digestion with hyaluronidase.The number and proportion of oocytes undergoing germinal vesicle breakdown (GVBD) and first polar body extrusion were assessed using an upright microscope (OLYMPUS, BX53 + DP72, Japan). Oocyte in Vitro Maturation (IVM) and Staging GV stage oocytes are placed in pre-prepared M16 culture drops (1–2 μL per oocyte), covered with paraffin oil, and incubated at 37 °C with 5% CO2. Observations are made every 2 hours for 16 h. The rupture of germinal vesicle (GVBD) and nuclear membrane (NEBD) is determined by observing the disappearance of the germinal vesicle under an optical microscope. After 6 h, GVBD oocytes continue to be cultured. Polar body extrusion (PBE) is noted from the 8th hour when the first polar body is visible, recorded until the 16th hour.The MII stage is identified by the expulsion of the first polar body. The MII ratio is calculated as the percentage of polar bodies expelled from the oocytes in each replicate out of the total number of oocytes in that replicate after 16 h of culture. Zygote collection and embryo culture Sperm capacitation involved euthanizing male ICR mice after 8 weeks, extracting sperm from the epididymis and vas deferens, and placing them in a capacitive solution (P/N 72020-T, SUDGEN BIOTECH). The sperm were incubated at 37 °C for 30 min. After mice were injected with 10 IU of PMSG for 48 h and 10 IU of hCG for 14 hours, MII stage oocytes were obtained for in vitro fertilization, with fertilization confirmed by the presence of two pronuclei. Selected zygotes were cultured in KSOM medium (M1435, Aibei Biotechnology Co., Ltd., Nanjing) under mineral oil (M8410, Sigma)at 37 °C with 5% CO2. 2-cell and 4-cell embryos were observed at 40 and 54 h post-hCG injection, respectively. HE staining and Follicular count Ovaries were fixed, embedded, and sliced into 5 μm sections to evaluate follicle numbers and identify pathological changes. Every tenth section was stained with hematoxylin and eosin for microscopic analysis. Two blinded pathologists independently graded and counted follicles using standardized criteria, recording the average counts. Follicles were categorized into five stages: primordial, primary, secondary, antral, and mature. Only follicles with visible oocytes were counted in the larger antral and mature stages to prevent errors, while this was not required for smaller primary and secondary follicles. Oocyte Reactive Oxygen Species Assay (ROS) Mix 1 μL of DCFH-DA probe with 1 mL of M2 medium, pipette the mixture into a sterile petri dish, and incubate at 37 °C with 5% CO2 for 1 h. Then, add washed MII oocytes to the ROS probe droplets and incubate at 37 °C for another hour. After incubation, transfer the oocytes to fresh M2 medium droplets, wash three times, and move them to a new M2 medium droplet. Finally, observe and photograph the oocytes under a Nikon ECLIPSE Ti2-E inverted fluorescence microscope at consistent fluorescence intensity. Visualization of the mitochondria by MitoTracker Green Mitochondrial distribution was visualized using MitoTracker Green staining (1/2000, Invitrogen, M7514). The dye was diluted in M16 medium to create culture droplets, which were equilibrated at 37 °C. Oocytes were incubated in these droplets at 37 °C for 30 min, then counterstained with Hoechst (1/1000 dilution, Thermo Fisher Scientific, R37605). They were then transferred to a glass-bottom dish for imaging with a laser scanning confocal microscope (LSM710, Carl Zeiss, Germany), using consistent intensity and exposure settings for all images. RNA isolation and m6A Quantification Total RNA was extracted from ovarian tissue using the Trizol reagent (Invitrogen, 15596026, USA) according to the manufacturer’s protocol. Subsequently, mRNA was isolated utilizing the Dynabeads® mRNA Purification Kit (Thermo Fisher). The purity of the mRNA was assessed using the NanoDrop method, and the samples were diluted to various concentrations. A dot blot assay was employed to evaluate changes in global m6A levels in mRNA. For the analysis of each sample, 1 μg of total RNA, quantified using a Thermo NanoDrop 2000c, was used. The N6-methyladenosine antibody (Synaptic Systems, m6A-202003, 1:1000) was used, and specific procedures were conducted as referenced in the literature. Signal intensity was analyzed using Image J software. MeRIP-seq Library Construction & Sequencing Total RNA underwent stringent quality control (NanoDrop, Bioanalyzer RIN > 7.0, gel electrophoresis). Poly(A) + RNA was purified using Dynabeads Oligo(dT), fragmented (86 °C, 7 min), and split into two libraries: Input (control) and IP (immunoprecipitated with m6A-specific antibody, 4 °C, 2 h). Immunoprecipitated RNA was reverse-transcribed (SuperScript™ II), and second-strand cDNA was synthesized incorporating dUTP. After end repair, A-tailing, and adapter ligation, size selection (AMPure XP beads) was performed. UDG treatment and PCR amplification generated final libraries (~300 bp inserts), which were sequenced (2×150 bp PE, Illumina NovaSeq™ 6000). Differential Gene Expression (RNA-seq) Differentially Expressed Genes (DEGs) were identified using DESeq2, applying thresholds of |log2FC | ≥ 1 (FC ≥ 2 or ≤ 0.5) and p-value < 0.05. m6A MeRIP-seq Data Analysis:Peak Calling: m6A modification sites (peaks) were identified from aligned IP and Input reads using the exomePeak R package. This tests genomic regions for significant IP read enrichment over Input using a Poisson model (default p-value < 0.05). Differential m6A Peak Analysis Differential methylation peaks (diffPeaks) were called using exomePeak, requiring |diffPeak.log2FC | ≥ 1, diffPeak.p-value < 0.05, and corresponding gene expression changes meeting DEG thresholds (|diffExp.gene.log2FC | ≥ 1, diffExp.gene.p-value < 0.05).Functional Analysis: Genes harboring differential m6A peaks underwent functional annotation and enrichment analysis (GO, KEGG). MeRIP-qPCR The procedures for total RNA extraction and mRNA purification have been previously detailed. Subsequently, the quantity and purity of the total RNA were assessed using the NanoDrop ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA). RNA integrity was evaluated using the Bioanalyzer 2100 (Agilent, CA, USA) and further confirmed through agarose gel electrophoresis. mRNA containing Poly(A) tails was isolated using oligo(dT) magnetic beads (Dynabeads Oligo (dT), Thermo Fisher, USA, Cat. No. 25-61005). Fragmentation of RNA was conducted at elevated temperatures, specifically at 86°C for 7 minutes, utilizing the NEBNext® Magnesium RNA Fragmentation Module (Cat#E6150S, USA). For immunoprecipitation, the Dynabeads Antibody Coupling Kit (Thermo Fisher, CA, USA) was combined with m6A antibody (Synaptic Systems, Germany, Cat. No. 202003) in an IP buffer composed of 50 mM Tris-HCl, 750 mM NaCl, and 0.5% Igepal CA-630. The immunoprecipitated product was reverse transcribed into cDNA using the Invitrogen SuperScript™ II Reverse Transcriptase (Cat#1896649, CA, USA). The synthesized cDNA, including both immunoprecipitated and input samples, was then prepared for subsequent MeRIP-qPCR and conventional RT-qPCR analyses. Primer sequences are provided in Supplementary Table 1. The enrichment m6A of yap was expressed as the enrichment percentage relative to the input sample (% Input)= 2Ct(Input)-Ct (MeRIP)×Fd× 100%, where Fd is the input dilution factor (1/8). Immunofluorescence staining For the immunolabeling of Bub1, IGF2BP3 (IMP3), CENPA, POLQ, and phosphorylated H2A.X, oocytes at the specified developmental stages were fixed in freshly prepared 4% paraformaldehyde (PFA) for 30 min. Subsequently, they were permeabilized with 0.3% Triton X-100 for 20 min. Following a blocking step in 0.2% bovine serum albumin (BSA) for 60 min, the samples were incubated with primary antibodies in a humidified chamber at 4 °C overnight. Details regarding the primary antibodies and their respective dilutions are provided in Supplementary Data 8. The oocytes were then subjected to three sequential washes with PBST to remove unbound primary antibodies, followed by a 2 h incubation with the appropriate secondary antibodies at room temperature. The samples were counterstained with DAPI for DNA visualization and mounted using SlowFade Diamond Antifade Mountant (Thermo Scientific™, 62248). Finally, the samples were placed on glass slides and examined using a confocal laser scanning microscope (LSM 710, Carl Zeiss, Germany). Supplemental Table 2 provides information on the antibodies. Small interference RNA microinjection Small interfering RNA (siRNA) targeting murine Igf2bp3 was procured from Jinsilui Biotechnology Co., Ltd. (Jiangsu, China). All microinjections were preformed using the DMi8 Leica micromanipulator, in conjunction with a needle puller (MP-500, Shenzhen Rayward Life Technology Co., Ltd., China) and a needle forging machine (MF-900, NARISHIGE, Japan). To prevent spontaneous germinal vesicle breakdown (GVBD) in oocytes, they were maintained in M2 medium supplemented with 2 μM milrinone. The siRNA was microinjected into the cytoplasm of oocytes at a volume of 5–10 picoliters at a concentration of 50 μM. Post-injection, the oocytes were cultured in M16 medium containing 2 μM milrinone for 24 h to achieve Igf2bp3 RNA knockdown under conditions of 37 °C and 5% CO₂. Following incubation, the oocytes were transferred to a milrinone-free medium for in vitro maturation. The rates of GVBD and polar body extrusion (PBE) were assessed at 6 and 16 h, respectively. The sequences of the siRNA used are provided in the Supplementary Table 3. Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Statistics and Reproducibility Data analysis was processed using SPSS 21.0 software. Mean ± Standard deviation was chosen to describe the data, depending on whether the data met the normal distribution. T-test or Mann-Whitney U test was used to compare within groups. One-way ANOVA or Kruskal-Wallis test was used for group comparisons. P < 0.05 was considered statistically significant. And graphs were drawn using Graphpad Prism 8 software. Sample sizes are indicated in the figure legends. Supplementary information Transparent Peer Review file Supplementary Information Description of Additional Supplementary files Supplementary Data 1-10 Reporting Summary Acknowledgements This study was supported the National Natural Science Foundation of China (82274568,82004407, 81874481), Guangdong Provincial Basic and Applied Research Fund Project (2022A1515220058), Guangzhou Science and Technology Planning Project (2025A03J4132), and Special Research Project for Traditional Chinese Medicine Science and Technology of Guangdong Provincial Hospital of Traditional Chinese Medicine (YN2024GZRPY050).This figure was created with elements from FigDraw (www.figdraw.com). Author contributions Y.L.: Writing–original draft, Visualization, Methodology, Formal analysis, Conceptualization. Y.Z.: Investigation, Analysis. J.L.: Methodology. G.N.: Methodology. F.C.: Methodology. H.Y.: Writing–review & editing, Supervision. Peer review Peer review information Communications Biology thanks Reza K. Oqani, Grigorios Fanourgakis, and the other, anonymous, reviewer for their contribution to the peer review of this work. Primary Handling Editors: Tuan Anh Nguyen and Mengtan Xing. A peer review file is available. Data availability The raw data MeRIP-seq data have been deposited in NCBI’s Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE309577. All the MeRIP-seq data generated in this study are summarized in Supplementary Data 1-8. The source data behind the graphs in the paper can be found in Supplementary Data 9. The data that support the findings of this study are available in the Supplementary Information of this article. All other data supporting the findings of this study are available from the corresponding author upon request. Competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary information The online version contains supplementary material available at 10.1038/s42003-025-09187-1. References Associated Data Supplementary Materials Transparent Peer Review file Supplementary Information Description of Additional Supplementary files Supplementary Data 1-10 Reporting Summary Data Availability Statement The raw data MeRIP-seq data have been deposited in NCBI’s Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE309577. All the MeRIP-seq data generated in this study are summarized in Supplementary Data 1-8. The source data behind the graphs in the paper can be found in Supplementary Data 9. The data that support the findings of this study are available in the Supplementary Information of this article. All other data supporting the findings of this study are available from the corresponding author upon request.